Drug intelligence / Profile preview

YH1151

Development stage: Preclinical
Lead developer: Yuhan

Overview

YH1151 is a preclinical-stage drug candidate being developed by Yuhan Corporation. As of the latest pipeline disclosures from Yuhan and its US subsidiary, AB Pharmaceuticals, the specific molecular target, therapeutic modality, and intended clinical indications for YH1151 remain undisclosed. The compound is part of the company's early-stage research and development portfolio aimed at expanding its therapeutic reach in undisclosed disease areas.

Beyond the preview

Go deeper on YH1151.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YH1151.

Explore the full profile